OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Taking Complexity to the Next Level
During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).
During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).
Approaching drug development with highly potent compounds gives rise to specific challenges, which can ultimately lead to increased costs and complex processes. In his presentation, Janssen will highlight ways in which companies can facilitate rapid time to clinic and market and will use a case study to emphasize the advantages of seamless integration of highly potent API and ADC operations.
HPAPIs and ADCs – a journey through high potencyTuesday Nov. 5, 201913:50–14:20ICSE Theatre (120G43)